Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Cumberland Pharmaceuticals (CPIX) over the last 15 years, with Sep 2025 value amounting to $684,224.

  • Cumberland Pharmaceuticals' Change in Accured Expenses fell 45.65% to $684,224 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year increase of 58.27%. This contributed to the annual value of -$991,359 for FY2024, which is 29.46% up from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Change in Accured Expenses of $684,224 as of Q3 2025, which was up 148.22% from -$1.4 million recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year Change in Accured Expenses high stood at $5.8 million for Q4 2022, and its period low was -$3.3 million during Q4 2023.
  • Its 3-year average for Change in Accured Expenses is -$339,220, with a median of -$600,043 in 2025.
  • In the last 5 years, Cumberland Pharmaceuticals' Change in Accured Expenses spiked by 2,957.92% in 2022 and then slumped by 185.82% in 2024.
  • Over the past 5 years, Cumberland Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at $2.1 million in 2021, then skyrocketed by 172.09% to $5.8 million in 2022, then plummeted by 157.46% to -$3.3 million in 2023, then soared by 90.20% to -$324,294 in 2024, then slumped by 45.65% to $684,224 in 2025.
  • Its last three reported values are $684,224 in Q3 2025, -$1.4 million for Q2 2025, and -$600,043 during Q1 2025.